… Iressa dose evaluation for advanced lung cancer phase II trials (IDEAL 1 and IDEAL 2) of
single agent gefitinib… day in pretreated patients with non-small cell lung cancer (NSCLC), found …

… of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor
mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403). Br J Cancer …

… patients who receive gefitinib first-line, outcome from gefitinib therapy in patients who had
… was equally longer with both gefitinib and docetaxel treatments in EGFR mutation-positive (…

… In the second study, including 88 patients in Europe and Australia, gefitinib was … with either
advanced non small cell lung, ovarian, head and neck, prostate, or colorectal cancer [11]. At …

… All published trials and abstracts citing gefitinib were … Gefitinib is a selective EGFR tyrosine
kinase inhibitor. Based on the … Recent trials have shown that gefitinib provided a 10% tumor …

… in patients with non–small-cell lung cancer (… gefitinib. One of these mutations, L858R (Leu→Arg),
is also found in NSCLC cell line H3255, which is very sensitive to gefitinib treatment…

… Gefitinib is an orally bioavailable, EGF receptor tyrosine kinase inhibitor and was the first …
non-small-cell lung cancer (NSCLC). Identification of objective tumor regressions with gefitinib …

… Four open-label, Phase I, dose-escalation trials determined gefitinib's safety profile in a …
receive intermittent gefitinib treatment (14 days treatment, followed by 14 days without treatment), …

… , gefitinib adds to the list of recommended first-line treatments for lung cancer harboring EGFR
… , clinical efficacy, and safety of gefitinib in major clinical trials and post-marketing studies. …

… During the last years, improvements in the knowledge of cancer biology led to identification
of new agents active against non-small-cell lung cancer (NSCLC). Drugs targeting the …